Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.48 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.45 |
| ▸ | CDC7 | O00311 | 12/20 | 0.43 |
| ▸ | CDK2 | P24941 | 10/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 9/20 | 0.43 |
| ▸ | PIM1 | P11309 | 9/20 | 0.43 |
| ▸ | PRKACA | P17612 | 9/20 | 0.43 |
| ▸ | HIPK2 | Q9H2X6 | 9/20 | 0.43 |
| ▸ | GSK3B | P49841 | 8/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 6/20 | 0.43 |
| ▸ | CDK9 | P50750 | 6/20 | 0.43 |
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.43 |
| ▸ | CDK7 | P50613 | 5/20 | 0.43 |
| ▸ | CDK8 | P49336 | 3/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 3/20 | 0.43 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.43 |
| ▸ | PAK4 | O96013 | 3/20 | 0.43 |
| ▸ | FLT3 | P36888 | 3/20 | 0.43 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2534550 | 0.86 | BRD4 (0.50) | BRD4DYRK1ACDC7CDK2ROCK2 | |
| SCHEMBL28805250 | 0.85 | DYRK1A (0.49) | BRD4DYRK1ACDC7CDK2ROCK2 | |
| SCHEMBL2534175 | 0.82 | DYRK1A (0.51) | BRD4DYRK1ACDC7CDK2ROCK2 | |
| SCHEMBL2528276 | 0.81 | DYRK1A (0.49) | BRD4DYRK1ACDC7CDK2ROCK2 | |
| SCHEMBL2534555 | 0.80 | DYRK1A (0.53) | BRD4DYRK1ACDC7CDK2ROCK2 | |
| SCHEMBL2528668 | 0.80 | DYRK1A (0.49) | BRD4DYRK1ACDC7CDK2ROCK2 | |
| SCHEMBL2534178 | 0.80 | CDC7 (0.63) | BRD4DYRK1ACDC7CDK2ROCK2 | |
| SCHEMBL2558076 | 0.80 | KIT (0.45) | BRD4DYRK1ACDC7CDK2ROCK2 | |
| SCHEMBL2528281 | 0.78 | DYRK1A (0.46) | BRD4DYRK1ACDC7CDK2ROCK2 | |
| SCHEMBL858219 | 0.78 | CDK8 (0.60) | BRD4DYRK1ACDC7CDK2ROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181246-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140357616-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBVIE INC (US) | 2014-12-04 | — | — | US | disclosed |
| US-8822446-B2 | Pyrrolopyridine inhibitors of kinases | ABBVIE INC. (US) | 2014-09-02 | — | — | US | disclosed |
| CN-103003274-A | Pyrrolopyridine inhibitors of kinases | ABBVIE INC | 2013-03-27 | — | — | CN | disclosed |
| EP-2560971-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-02-27 | — | — | EP | disclosed |
| WO-2011133388-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-10-27 | — | — | WO | disclosed |
| US-20110257152-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140357616-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | BRD4 1274/4885DYRK1A 355/4885CDC7 1/4885 |
| US-20110257152-A1 | PYRROLOPYRIDINE INHIBITORS OF KINASES | CDC7, MAP3K7, CDK1 | BRD4 1274/4885DYRK1A 355/4885CDC7 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.